GlassScriptPhysician profile
Samuel A Minaker
NPI 1174194955
$48,290.40
in general payments reported to CMS, 2019-2025
16 companies · $28K in 2025
The $28K reported for 2025 was more than what 97% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $122 · 2022: $239 · 2023: $1,680 · 2024: $19K · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $31K · Food and Beverage: $7,275 · Travel and Lodging: $5,237 · Honoraria: $4,913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $30,504.25 |
| Food and Beverage | $7,274.89 |
| Travel and Lodging | $5,236.89 |
| Honoraria | $4,913.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $10,635.59 | 2022-2025 | Vabysmo, Susvimo |
| Ocular Therapeutix, INC. | $10,212.24 | 2024-2025 | Dextenza |
| Abbvie INC. | $7,925.34 | 2024-2025 | |
| Apellis Pharmaceuticals, INC. | $7,113.28 | 2023-2025 | Syfovre |
| Alimera Sciences, INC. | $4,327.46 | 2023-2024 | Iluvien, Yutiq |
| Harrow Eye, LLC | $2,855.57 | 2025 | Iheezo, Triesence |
| Eyepoint US, INC. | $2,307.29 | 2023-2024 | |
| Astellas Pharma US INC | $978.36 | 2023-2025 | Izervay |
| Regeneron Healthcare Solutions, INC. | $509.70 | 2021-2025 | Eylea Hd, Eylea |
| Alcon Vision LLC | $417.55 | 2024 | |
| Regeneron Pharmaceuticals, INC. | $373.46 | 2024-2025 | Eylea Hd |
| Ani Pharmaceuticals, INC. | $306.53 | 2024-2025 | Purified Cortrophin Gel, Iluvien |
| Bausch & Lomb Americas INC. | $123.38 | 2022-2025 | Xipere |
| Genentech, INC. | $111.48 | 2025 | Vabysmo |
| Samsara Vision | $59.38 | 2025 | Implantable Miniature Telescope (Imt By Dr. Isaac Lipshitz) |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $33.79 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Minaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.